Conditions: Epilepsy
Keywords: Epilepsy Partial Onset epilepsy Lennox-Gastaut Syndrome Open-label extension study
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 4
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the long-term safety and tolerability of retigabine/ezogabine as an adjunctive treatment in subjects with either partial onset seizures (12 to \< 18 years old) or Lennox-Gastaut Syndrome (12 to \<30 years old) who have participated in a previous ("parent") study.

Detailed description:
Epilepsy is among the most common serious neurologic disorders in childhood. Medicines with novel actions of mechanisms of action are needed to try to address the unmet clinical need for seizure control in patients with treatment-resistant epilepsy. The purpose of this study is to evaluate the long-term safety and tolerability of retigabine/ezogabine as an adjunctive treatment in subjects with either partial onset seizures (12 to \< 18 years old) or Lennox-Gastaut Syndrome (12 to \<30 years old) who have participated in a previous ("parent") study.

Arms:
arm 1: retigabine/ezogabine will be administered three times a day (TID) as add-on therapy based on weight

Interventions: intervention 1: retigabine/ezogabine
Intervention descriptions: intervention 1: retigabine/ezogabine will be administered three times a day (TID) as add-on therapy based on weight

Protocol document: